Coherus BioSciences Inc Conference Call to Discuss FDA's Issuance of Complete Response Letter for its Biologics License Applicat

12/6/2017 8:00

Conference Call Coherus BioSciences Inc

Coherus BioSciences Inc Conference call will be held on Jun 12, 2017. During the earnings conference call's session Coherus BioSciences Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Coherus BioSciences Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a late-stage clinical biologics platform company focused on the global biosimilar market. Biosimilars are an emerging class of protein-based therapeutics with high similarity to approved originator products on the basis of various physicochemical and structural properties, as well as in terms of safety, purity and potency. Our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Since our founding in 2010, we have advanced three product candidates into Phase 3 or Biologics License Application (BLA), enabling clinical development and entered into partnerships with two global pharmaceutical companies and one strategic biologics manufacturer.    
Read more Conference Call

Coherus BioSciences Inc (CHRS)

3750 State Road, Bensalem Pennsylvania 19020, United States